a person with glasses

Life Sciences

  • Frontage Laboratories in its acquisition of Nucro Technics, an Ontario-based Contract Support Organization for the pharmaceutical, biotech, medical device, and marijuana industries.
  • Elanco Animal Health (NYSE:ELAN) in four agreements for technology development with biotechnology company EVAH Corp.
  • Sansero Life Sciences Inc. and Rise Wellness on their merger with CannaGlobal to create a new international psychedelic company.
  • Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, on its US$200 million underwritten public offering.
  • Aurinia Pharmaceuticals Inc. in its US$191.7 firmly underwritten public equity financing as a follow on to its successful Phase 3 clinical study in lupus nephritis.
  • Citoxlab, a private non-clinical contract research organization (CRO), in its €448 million sale to Charles River Laboratories International, Inc. (NYSE: CRL), a company specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
  • Wildflower Brands Inc. (CSE: SUN, OTC: WLDFF), an integrated health and wellness company, in its $45 million acquisition of City Cannabis Corp., a premier licenced cannabis retailer in British Columbia.
  • The Supreme Cannabis Company, Inc., a TSX, OTC and Frankfurt listed global diversified portfolio of distinct cannabis companies, products and brans, in its $20 million acquisition of Truverra Inc., a private cannabis company, serving the Canadian and international cannabis markets through its wholly-owned subsidiaries, Canadian Clinical Cannabinoids Inc. and Truverra (Europe) B.V. As a result of the transaction, City Cannabis is the only British Columbia based cannabis retailer to go public. In addition, in filing and prosecution strategy and mark protection for a large cannabis industry member operating in the medical and recreational space. Such strategy includes navigating new regulations and impacts on branding.
  • Elanco Animal Health Incorporated (NYSE: ELAN), an animal healthcare company, in its $78.5 million acquisition of Prevtec Microbia Inc., a biotechnology startup specializing in the development of vaccines that help prevent bacterial diseases in food animals, including inventory and pipeline assets.
  • Arbutus Biopharma Corporation in its C$37 million joint venture partnership with Roivant Sciences Ltd. to form Genevant Sciences.
  • CanniMed Therapeutics Inc. in its defense against a $586 million all stock hostile bid from Aurora Cannabis Inc. and the negotiation of a sweetened friendly $1.23 billion cash and stock offer.
  • Millennium Pharmaceuticals Inc., in appealing the legal errors in Teva Canada Limited v. Janssen Inc. et al. This is necessary to restore validity to our client’s patents and ensure the law in Canada is not weakened.
  • Eli Lilly Canada Inc., Eli Lilly and Company, Lilly Del Caribe, Inc., Lilly S.A., and ICOS Corporation in defending against all marketing generic companies in a number of patent infringement matters relating to CIALIS® and ADCIRCA® tadalafil products. In all cases, allegations of infringement of three patents, relating to unit doses, formulations and processes, are asserted.
  • Hollyweed North Cannabis Inc. in co-ordinating and filing numerous trademarks for use in the cannabis industry, including working with local counsel in other jurisdictions to protect the marks while navigating a challenging regulatory environment.
  • Desjardins Capital Markets, as lead underwriter, in Savaria Corporation’s C$70.75 million bought deal private placement, a TSX-listed leader in the accessibility industry.
  • Titan Medical Inc., a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery in its US$28.75 million public offering, as well as its Common Share Purchase Agreement of up to US$35 million.
  • Resverlogix Corp., a late-stage clinical biotechnology company in its C$6.6 million private placement with Shenzhen Hepalink Pharmaceutical Co. Ltd, its C$15.1 million private placement with Shenzhen Hepalink and other investors, and its C$15.2 million marketed public offering.
  • Frontage Laboratories in its acquisition of Nucro Technics, an Ontario-based Contract Support Organization for the pharmaceutical, biotech, medical device, and marijuana industries.
  • Elanco Animal Health (NYSE:ELAN) in four agreements for technology development with biotechnology company EVAH Corp.
  • Sansero Life Sciences Inc. and Rise Wellness on their merger with CannaGlobal to create a new international psychedelic company.
  • Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, on its US$200 million underwritten public offering.
  • Aurinia Pharmaceuticals Inc. in its US$191.7 firmly underwritten public equity financing as a follow on to its successful Phase 3 clinical study in lupus nephritis.
  • Citoxlab, a private non-clinical contract research organization (CRO), in its €448 million sale to Charles River Laboratories International, Inc. (NYSE: CRL), a company specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
  • Wildflower Brands Inc. (CSE: SUN, OTC: WLDFF), an integrated health and wellness company, in its $45 million acquisition of City Cannabis Corp., a premier licenced cannabis retailer in British Columbia.
  • The Supreme Cannabis Company, Inc., a TSX, OTC and Frankfurt listed global diversified portfolio of distinct cannabis companies, products and brans, in its $20 million acquisition of Truverra Inc., a private cannabis company, serving the Canadian and international cannabis markets through its wholly-owned subsidiaries, Canadian Clinical Cannabinoids Inc. and Truverra (Europe) B.V. As a result of the transaction, City Cannabis is the only British Columbia based cannabis retailer to go public. In addition, in filing and prosecution strategy and mark protection for a large cannabis industry member operating in the medical and recreational space. Such strategy includes navigating new regulations and impacts on branding.
  • Elanco Animal Health Incorporated (NYSE: ELAN), an animal healthcare company, in its $78.5 million acquisition of Prevtec Microbia Inc., a biotechnology startup specializing in the development of vaccines that help prevent bacterial diseases in food animals, including inventory and pipeline assets.
  • Arbutus Biopharma Corporation in its C$37 million joint venture partnership with Roivant Sciences Ltd. to form Genevant Sciences.
  • CanniMed Therapeutics Inc. in its defense against a $586 million all stock hostile bid from Aurora Cannabis Inc. and the negotiation of a sweetened friendly $1.23 billion cash and stock offer.
  • Millennium Pharmaceuticals Inc., in appealing the legal errors in Teva Canada Limited v. Janssen Inc. et al. This is necessary to restore validity to our client’s patents and ensure the law in Canada is not weakened.
  • Eli Lilly Canada Inc., Eli Lilly and Company, Lilly Del Caribe, Inc., Lilly S.A., and ICOS Corporation in defending against all marketing generic companies in a number of patent infringement matters relating to CIALIS® and ADCIRCA® tadalafil products. In all cases, allegations of infringement of three patents, relating to unit doses, formulations and processes, are asserted.
  • Hollyweed North Cannabis Inc. in co-ordinating and filing numerous trademarks for use in the cannabis industry, including working with local counsel in other jurisdictions to protect the marks while navigating a challenging regulatory environment.
  • Desjardins Capital Markets, as lead underwriter, in Savaria Corporation’s C$70.75 million bought deal private placement, a TSX-listed leader in the accessibility industry.
  • Titan Medical Inc., a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery in its US$28.75 million public offering, as well as its Common Share Purchase Agreement of up to US$35 million.
  • Resverlogix Corp., a late-stage clinical biotechnology company in its C$6.6 million private placement with Shenzhen Hepalink Pharmaceutical Co. Ltd, its C$15.1 million private placement with Shenzhen Hepalink and other investors, and its C$15.2 million marketed public offering.

Key Contacts

View All Professionals

Insights

View All Insights
View All Insights

Stay Up to Date

Subscribe to receive our insights and perspectives on the latest legal developments that will affect you.
Register